TheEdgeResearch
Home / Stocks / OPORF

hVIVO plc (OPORF)

OTC Healthcare Medical - Diagnostics & Research
$0.08 ▲ +0.00%
Market Cap
$54.2M
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Beta
1.71
52-Wk Range
0.0788-0.24
CEO
Yamin Mohammed Khan
Country
GB
Currency
USD

hVIVO plc operates in the Medical - Diagnostics & Research industry of the Healthcare sector, headquartered in London, GL, GB. The stock last traded at $0.08, up 0.00% on the session, giving a market capitalisation of $54.2M. On trailing twelve-month figures it carries a trailing P/E of -2.53, a net margin of -31.8%. Its beta of 1.71 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
-2.53
Price / Sales
0.81
Price / Book
0.98
EV / EBITDA
-3.47
Gross margin
-12.1%
Operating margin
-37.2%
Net margin
-31.8%
Return on equity
—
Debt / equity
0.43
Current ratio
1.21
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
376
IPO date
2020-06-05
Headquarters
London, GL, GB
About hVIVO plc

hVIVO plc (HVO) operates as a premier full-service Contract Research Organisation (CRO) focused on early-phase clinical development, globally recognized as the leader in human challenge trials. The company provides a complete spectrum of clinical development services to a wide-ranging and growing client base, which includes seven of the world's ten largest biopharmaceutical companies. A key specialisation for hVIVO is orchestrating human challenge trials across numerous infectious and respiratory diseases, utilising its advanced, London-based quarantine facility, the largest of its kind globally. Additionally, the company offers extensive virology and immunology laboratory services through its hLAB division. Through its German subsidiary, CRS, hVIVO manages a 120-bed capacity across sites in Mannheim and Kiel, delivering early-phase clinical trial expertise, including first-in-human and proof-of-concept studies. Its other subsidiary, Venn Life Sciences, contributes to the biopharma sector by providing specialist early drug development consulting and biometry services. The Group collectively offers integrated drug development solutions, covering stages from preclinical research up to Phase II trials, supported by patient recruitment via FluCamp. Moreover, its five clinical sites facilitate outpatient Phase II and III trials, ensuring a streamlined and effective transition from drug discovery to late-stage development.

Comparable companies

hVIVO plc is most often compared with the following Healthcare names:

BHCCFEVGRFFGHQFGNFTFHNSBFORPEFORYZFSLNCFSPHDFTRGNF
More research on OPORF
OPORF technical analysis OPORF TheEdge Score Compare against peers
Open full interactive analysis & DCF →